Peijia Medical Limited Total Liabilities

Latest as of December 2025: €798.71 Million EUR ≈ $933.77 Million USD

Peijia Medical Limited total liabilities. Based on the latest financial reports, Peijia Medical Limited (4WO) has total liabilities worth €798.71 Million EUR (≈ $933.77 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check 4WO cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.

Total Liabilities of Peijia Medical Limited (2018–2025)

Total liabilities of Peijia Medical Limited from 2018 to 2025. This chart illustrates how Peijia Medical Limited's total liabilities have evolved over time, based on quarterly financial data.

Peijia Medical Limited Competitors by Total Liabilities

The table below lists competitors of Peijia Medical Limited ranked by their total liabilities.

Company Country Total Liabilities
Hyliion Holdings Corp.
NYSE:HYLN
USA $12.38 Million
Chien Kuo Construction Co Ltd
TW:5515
Taiwan NT$5.84 Billion
Trifork Holding AG
CO:TRIFOR
Denmark Dkr164.52 Million
Jiangsu Xinning Modern Logist
SHE:300013
China CN¥677.72 Million
Shandong Sito Bio-technology Co Ltd
SHE:300583
China CN¥1.16 Billion
Canopy Growth Corp
NASDAQ:CGC
USA $415.29 Million
Microtek International Inc
TW:2305
Taiwan NT$569.67 Million
Fujian Superpipe
SHE:300198
China CN¥1.60 Billion

Liability Composition Analysis (2018–2025)

This chart breaks down Peijia Medical Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see 4WO total asset value.

Liquidity & Leverage Metrics

Peijia Medical Limited Total Liabilities Ratios Explained

Peijia Medical Limited total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.

Metric Value Description
Current Ratio 1.21 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.43 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.30 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Peijia Medical Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Peijia Medical Limited (2018–2025)

The table below shows the annual total liabilities of Peijia Medical Limited from 2018 to 2025.

Year Total Liabilities Change
2025-12-31 €798.71 Million
≈ $933.77 Million
+24.00%
2024-12-31 €644.11 Million
≈ $753.03 Million
+61.88%
2023-12-31 €397.88 Million
≈ $465.17 Million
-41.39%
2022-12-31 €678.86 Million
≈ $793.66 Million
+369.85%
2021-12-31 €144.48 Million
≈ $168.92 Million
+112.49%
2020-12-31 €67.99 Million
≈ $79.49 Million
-95.27%
2019-12-31 €1.44 Billion
≈ $1.68 Billion
+435.05%
2018-12-31 €268.70 Million
≈ $314.14 Million
--

About Peijia Medical Limited

F:4WO Germany Medical Devices
Market Cap
$299.00 Million
€255.75 Million EUR
Market Cap Rank
#14522 Global
#1466 in Germany
Share Price
€0.38
Change (1 day)
-2.05%
52-Week Range
€0.38 - €0.78
All Time High
€3.90
About

Peijia Medical Limited, together with its subsidiaries, engages in the research, development, manufacturing, and sales of transcatheter valve therapeutic and neurointerventional procedural medical devices in the People's Republic of China. It operates through Transcatheter Valve Therapeutic Business, Neurointerventional Business, and Future Technology Business segments. The company's products inc… Read more